TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• TuHURA Biosciences has a “Moderate Buy” consensus rating from six analysts, with five buy ratings and one sell rating. The average 12-month price target is $9.00, substantially above the reported share price of $1.95.
• Institutional investors made several recent purchases, including new stakes by Jefferies Financial, Squarepoint Ops, HSBC, and Two Sigma Securities; however, institutional ownership remains low at 0.62%.
• The company reported a quarterly loss of $0.14 per share, slightly better than the expected $0.15 loss. TuHURA is a clinical-stage biotechnology company developing immuno-oncology therapies, including its lead candidate IFx-2.

TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $9.00.

HURA has been the subject of a number of recent research reports. Citizens Jmp restated a "market outperform" rating and issued a $9.00 price objective on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TuHURA Biosciences in a report on Friday, July 17th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HURA. Squarepoint Ops LLC acquired a new position in shares of TuHURA Biosciences in the 2nd quarter worth approximately $81,000. HighTower Advisors LLC lifted its position in shares of TuHURA Biosciences by 42.5% during the 2nd quarter. HighTower Advisors LLC now owns 30,151 shares of the company's stock worth $71,000 after buying an additional 8,999 shares during the period. Two Sigma Securities LLC acquired a new stake in TuHURA Biosciences in the 2nd quarter valued at $33,000. Hsbc Holdings PLC acquired a new stake in TuHURA Biosciences in the 2nd quarter valued at $69,000. Finally, Jefferies Financial Group Inc. bought a new stake in TuHURA Biosciences in the second quarter valued at $98,000. Institutional investors own 0.62% of the company's stock.

TuHURA Biosciences Price Performance

Shares of NASDAQ:HURA opened at $1.95 on Wednesday. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $3.43. The firm has a market capitalization of $124.27 million, a PE ratio of -3.61 and a beta of -0.21. The business's 50 day moving average is $2.11 and its 200-day moving average is $2.22. The company has a current ratio of 0.18, a quick ratio of 0.18 and a debt-to-equity ratio of 0.20.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. Sell-side analysts predict that TuHURA Biosciences will post -0.55 earnings per share for the current year.

About TuHURA Biosciences

TuHURA Biosciences, Inc NASDAQ: HURA is a clinical-stage biotechnology company focused on developing therapies designed to overcome immune suppression in the tumor microenvironment and improve responses to cancer treatment. The company's research is centered on immuno-oncology approaches intended to stimulate both innate and adaptive immune responses against tumors.

TuHURA's lead program, IFx-2, is an investigational intratumoral immunotherapy and cancer vaccine candidate designed to reprogram the tumor environment and promote an immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.